



*cancers*



an Open Access Journal by MDPI

## Novel Strategies to Mitigate Cancer Therapy Side Effects

Guest Editor:

### Dr. Shuiying Hu

Division of Outcomes and  
Translational Sciences, College of  
Pharmacy & Comprehensive  
Cancer Center, The Ohio State  
University, Columbus, OH 43210,  
USA

Deadline for manuscript  
submissions:

**closed (22 November 2022)**

### Message from the Guest Editor

Dear Colleagues,

Although the effectiveness of cancer therapy has improved dramatically in the last few decades, side effects associated with small-molecule cancer drugs remain a tremendous health problem worldwide, as they negatively impact treatment outcome and diminish overall quality of life. The improved understanding of the molecular and/or cellular mechanisms that underlies the development of cancer therapy-induced side effects has resulted in continuing efforts to predict, prevent, and/or treat potentially debilitating adverse events.

In this Special Issue, we invite experts from the field to highlight novel strategies to mitigate cancer therapy-induced side effects, including both predictive and preventative interventions (including those involving genotyping, biomarker phenotyping, population PK, targeted drug treatment), as well as innovative treatment approaches (including symptom management and mechanism-based reversal of injury).



[mdpi.com/si/82507](https://mdpi.com/si/82507)

# Special Issue



*cancers*



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI